secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026636
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly
--------------------------------------------------------------------------------

- Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.
- Q4 GAAP net loss $9.8M improved from $26.6M; adjusted net loss $5.8M; adjusted EBITDA negative $3.6M.
- Full-year 2024 revenue $335.7M (+6.4%); operating loss $42.5M (improved from $109.4M); cash $117.4M, no debt.
- Company provides 2025 growth outlook; announced strategic collaboration with Yuwell to expand product portfolio and global reach.
- Pending U.S. introduction of Simeox airway clearance therapy highlighted as key future growth driver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017025026636/0000950170-25-026636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017025026636/ingn-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer